Get the Daily Brief
Latest Biotech News
Epigenovo commercializes single‑cell chromatin assay for FFPE samples
Swedish spinout Epigenovo is commercializing scFFPE‑ATAC, a high‑throughput single‑cell chromatin‑accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) tissues. The method,...
AbCellera, Bruker settle patent fight: $36M plus royalties
AbCellera and Bruker reached a settlement resolving longstanding patent litigation tied to single‑cell antibody discovery and microfluidic technologies. Under the agreement Bruker will pay...
JAX completes NYSCF takeover: unified stem‑cell and genetics engine launches
The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and held a ribbon‑tying event to mark the launch of a unified nonprofit research organization in New York...
Brinsupri clinical setback slashes Insmed market cap – readout problem
BioCentury reported a clinical setback for Insmed’s Brinsupri that triggered a sharp market reaction and a reduction in the company’s market capitalization. The report details clinical data or...
BioMarin to buy Amicus for $4.8B — rare disease push
BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion in cash, consolidating two rare-disease portfolios. The deal transfers Amicus’ approved therapies for Fabry (Galafold) and Pompe...
Cytokinetics wins FDA approval for heart drug Myqorzo
The FDA granted Cytokinetics its first U.S. drug approval for Myqorzo to treat obstructive hypertrophic cardiomyopathy, ending a 27-year pursuit for the company. Cytokinetics said it will begin...
Phase III halt after fatal ILD events in ADC trial
Daiichi Sankyo paused enrollment in the phase III IDeate-Lung02 study of the antibody-drug conjugate ifinatamab deruxtecan following a higher-than-anticipated incidence of fatal interstitial lung...
Epigenovo commercializes single-cell FFPE chromatin assay
Swedish spinout Epigenovo is commercializing scFFPE-ATAC, a high‑throughput single-cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) tissue. The company...
Galux and Boehringer ink AI protein-design research pact
South Korean AI-protein design firm Galux signed a research agreement with Boehringer Ingelheim to explore AI-driven design of purpose-specific protein therapeutics. Galux will validate AI methods...
Parse Biosciences and Codebreaker map variant effects in single cells
Parse Biosciences and Codebreaker Labs launched a collaboration to couple Codebreaker’s engineered variant libraries with Parse’s single-cell transcriptomics to determine how genetic variants...
Wasatch and Agilent roll out targeted nanopore methylation service
Wasatch BioLabs and Agilent announced a co-marketing agreement for a targeted nanopore methylation sequencing assay developed jointly and available under early access. The service pairs Wasatch’s...
Antisense oligo rescues developmental defects in SMA organoids
A Nature Communications study reported that targeted antisense oligonucleotide (ASO) therapy reversed developmental defects in spinal muscular atrophy (SMA) organoid models. The team demonstrated...
MINFLUX microscopy maps cardiac ryanodine receptor in 3D
Researchers led by Clowsley, Meletiou and Janicek applied MINFLUX super‑resolution microscopy to resolve the three‑dimensional subunit architecture and orientation of the cardiac ryanodine...
Gut microbiome signatures predict malaria severity in monkeys and humans
A Nature Communications paper linked specific gut microbiome signatures to the severity of Plasmodium infections across rhesus macaques and humans. The study identified microbial taxa and...
BioMarin buys Amicus for $4.8 billion — rare-disease portfolio expands
BioMarin agreed to acquire Amicus Therapeutics in an all-cash deal valued at $4.8 billion, adding two marketed rare-disease therapies and late-stage assets to BioMarin’s portfolio. The boards of...
Cytokinetics wins FDA approval for obstructive hypertrophic cardiomyopathy drug
The FDA approved Cytokinetics’ Myqorzo, marking the company’s first U.S. drug approval for obstructive hypertrophic cardiomyopathy after a decades-long effort. Myqorzo will enter the market as a...
Patient deaths halt Merck–Daiichi ADC phase III — safety review launched
Daiichi Sankyo and Merck paused enrollment in the Phase III IDeate-Lung02 trial of an antibody-drug conjugate (I-DXd/ifinatamab deruxtecan) after a higher-than-anticipated incidence of grade 5...
White House finalizes nine drugmakers' pricing deals — most‑favored‑nation push
The White House announced accords with nine major drugmakers to lower certain drug prices in Medicaid, extending a ‘most favored nation’ style pricing push across the supply chain. Companies...
Trump administration suspends NIH operations — $1.5B in grants canceled
The Trump administration imposed restrictions across the NIH and other federal agencies that froze grant reviews, external communications, travel, and hiring, and later proposed a 15% cap on...
Epigenovo commercializes scFFPE‑ATAC — single‑cell chromatin for archived tissue
Swedish spinout Epigenovo is commercializing scFFPE‑ATAC, a single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) tissue, and is raising funds to kit...